| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6177122 | European Urology | 2016 | 7 Pages |
Abstract
We assessed adverse events in patients with metastatic castration-resistant prostate cancer during long-term treatment with a low dose of a corticosteroid. We found that long-term treatment with this low-dose corticosteroid is safe and tolerable.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Karim Fizazi, Kim N. Chi, Johann S. de Bono, Leonard G. Gomella, Kurt Miller, Dana E. Rathkopf, Charles J. Ryan, Howard I. Scher, Neal D. Shore, Peter De Porre, Anil Londhe, Tracy McGowan, Nonko Pelhivanov, Robert Charnas, Mary B. Todd, Bruce Montgomery,